#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neutropenia Malignant peritoneal neoplasm Angiosarcoma non-metastatic Hepatitis B Hairy cell leukaemia recurrent Chondrosarcoma metastatic Hereditary ataxia Ocular myasthenia Erythema Follicle centre lymphoma follicular grade I II – III refractory Neoplasm Immune-mediated enterocolitis Prophylaxis against transplant rejection Congenital leptin deficiency Ovarian cancer More trials…

    Learn about Rare Diseases

    Prader-Willi syndrome MELAS syndrome – Life with Disease Antisynthetase syndrome – Treatment Hereditary neuropathic amyloidosis – Treatment Pulmonary fibrosis Glycogen storage disease type I – Trials in Disease Urea cycle disorder – Treatment Pleural mesothelioma malignant – Basic Information Idiopathic pulmonary fibrosis – Treatment Lennox-Gastaut syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    LTX-002 SODIUM Cetrimide SULBACTAM SODIUM Pralsetinib Regn9933 AZD3632 Cat Epithelia Ixazomib Felzartamab Upacicalcet Sodium Hydrate XYLOMETAZOLINE HYDROCHLORIDE Gemlapodect Masupirdine Perindopril Tert-Butylamine Crovalimab Umeclidinium Bromide Dipyridamole GOCATAMIG Blu-451 LY3841136 SODIUM More therapies…

    Learn about Your Condition

    Metastatic gastric cancer Adenovirus infection Phaeochromocytoma Ovarian granulosa cell tumour Oedema Oxygen saturation Lipid metabolism disorder Lichen planus Cerebral amyloid angiopathy Propionic acidaemia Pharyngeal cancer stage I Obesity Tumour of ampulla of Vater Hypertrophic cardiomyopathy Blood iron increased More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Acromegaly

  • Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acromegaly
    Investigated Drugs:
    • Lanreotide
    • Octreotide
    Austria Belgium Bulgaria Denmark Estonia France +10

  • Study on the Effects of Pegvisomant and Somatropin on Liver Fat Metabolism in Patients with Acromegaly and Healthy Individuals

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Acromegaly
    Investigated Drugs:
    • PEGVISOMANT
    • Somatropin
    Austria

  • Short-Acting Pasireotide Test to Predict Treatment Response in Patients with Acromegaly

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Pasireotide
    Spain

  • Study of ALXN2420 with somatostatin analogs for adults with acromegaly to evaluate effectiveness in lowering IGF-1 levels

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Acromegaly
    Investigated Drugs:
    • ALXN2420
    • Octreotide Acetate
    Denmark Hungary Italy Lithuania The Netherlands Poland +1

  • Study on the Long-Term Safety and Efficacy of Paltusotine for Patients with Acromegaly

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Acromegaly
    Investigated Drugs:
    • Paltusotine
    Germany Greece Hungary

  • Study on the Safety and Effectiveness of Paltusotine for Patients with Acromegaly

    Not recruiting

    3 1
    Investigated Drugs:
    • Paltusotine
    Belgium Bulgaria France Hungary Italy Poland
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!